Ellington Management Group’s Anika Therapeutics ANIK Stock Holding History

Ellington Management Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,907	Closed	-$239K	–	574
2019 Q1	$239K	Buy	+7,907	New	+$271K	0.04%	426
2016 Q1	–	Sell	-11,049	Closed	-$422K	–	492
2015 Q4	$422K	Sell	11,049 -7,599	-41%	-$291K	0.15%	178
2015 Q3	$594K	Buy	+18,648	New	+$650K	0.17%	180
2015 Q2	–	Sell	-4,900	Closed	-$202K	–	676
2015 Q1	$202K	Buy	+4,900	New	+$198K	0.04%	596
2014 Q4	–	Sell	-9,500	Closed	-$348K	–	554
2014 Q3	$348K	Buy	9,500 +4,300	+83%	+$186K	0.24%	125
2014 Q2	$241K	Buy	+5,200	New	+$231K	0.11%	295
2014 Q1	–	Sell	-12,500	Closed	-$477K	–	600
2013 Q4	$477K	Buy	+12,500	New	+$386K	0.17%	190

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ellington Management Group's ANIK Position: Q2 2019 in Review

Ellington Management Group sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 7,907 shares — an estimated $239K sold.

Ellington Management Group first reported a position in ANIK in Q4 2013 and held it in 7 quarters. The position peaked at $594K in Q3 2015. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

Ellington Management Group reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
Ellington Management Group sold 7,907 Anika Therapeutics shares in Q2 2019, an estimated $239K.
Ellington Management Group first reported a position in Anika Therapeutics in Q4 2013 and held it in 7 quarters.
Ellington Management Group's Anika Therapeutics position peaked at $594K in Q3 2015.
165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.